High-cost generic drugs--implications for patients and policymakers.
Some older generic drugs have become very expensive, owing to factors including drug shortages, supply disruptions, and consolidations in the generic-drug industry. But generics manufacturers that legally obtain a market monopoly can also unilaterally raise prices.
From the Department of Medicine, University of Minnesota, Minneapolis (J.D.A., W.M.S.); the Department of Medicine, Regions Hospital, St. Paul, MN (J.D.A., W.M.S.); and the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (A.S.K.).
Jonathan D
JD
Alpern
William M
WM
Stauffer
Aaron S
AS
Kesselheim
D015766:Albendazole / Q000191:economics*; D000977:Antiparasitic Agents / Q000191:economics*; D016363:Antitrust Laws; D016527:Drug Costs / Q000639:trends; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000191:economics*; D006801:Humans; D008484:Medicaid / Q000191:economics; D014481:United States; D014485:United States Federal Trade Commission; D014486:United States Food and Drug Administration
D000977:Antiparasitic Agents; D016568:Drugs, Generic; D015766:Albendazole